[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618466":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":35,"locations":41,"responsibleParty":60,"collaborators":11,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":11,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":11,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":44,"whyStopped":11,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Moon (Guangzhou) Biotechnology Co., Ltd.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo + Escitalopram","PLACEBO_COMPARATOR",null,[13,14],"Drug: Placebo","Combination Product: Escitalopram",{"label":16,"type":17,"description":11,"interventionNames":18},"Probiotics + Escitalopram","EXPERIMENTAL",[19,14],"Drug: Probiotic",[21,26,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","Probiotic","Participants receive Probiotic product once daily by oral, 60B CFU\u002Fday for 3 months.",[16],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"Placebo","Participants receive Placebo once daily by oral for 3 months.",[9],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"COMBINATION_PRODUCT","Escitalopram","Participants receive Escitalopram Oxalate Tablets once daily by oral, 10mg\u002Fday for 3 months.",[9,16],[36],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Baojia Huang","CONTACT","86-020-31603387","huangbj@moonbio.com",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":11,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"The First Affiliated Hospital of Guangdong Pharmaceutical University","RECRUITING","Guangzhou","Guangdong","China","CN",{"type":50,"coordinates":51},"Point",[52,53],113.25,23.11667,{"lat":53,"lon":52},[56],{"name":57,"role":38,"phone":58,"phoneExt":11,"email":59},"IRB, First Affiliated Hosp, Guangdong Pharm Univ","86-020-87609616","gylunli@163.com",{"type":61,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100618466","efficacy-and-safety-of-probiotics-for-anxiety-depression-100618466",false,"NCT07331987","Efficacy and Safety of Probiotics for Anxiety Depression","A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Efficacy and Safety of Probiotics in Participants With Anxiety Depression","Inclusion Criteria:\n\n* 1\\) Age: 18-60 years old; Gender: male or female.\n* 2\\) Meets the diagnostic criteria of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) for a mild-to-moderate depressive or anxiety symptoms.\n* 3\\) Hamilton Depression Rating Scale (HAM-D-24) score ≥ 8 or Hamilton Anxiety Rating Scale (HAM-A-14) score ≥ 7 at screening.\n* 4\\) Has no used of anxiolytic or antidepressant medications (including traditional Chinese patent medicines), with the exception of Escitalopram Oxalate, within 2 weeks prior to the first dose.\n* 5\\) For participants of childbearing potential (male or female): Must agree to use least one medically approve form of contraception (e.g., intrautering device \\[IUD\\], oral contraceptives, or condoms) throughout the trial. For female participants of childbearing potential: Must have a negative urine pregnancy test at screening and must be non-lactating.\n* 6\\) The participant is willing and be able to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* 1\\) HAM-D-24 score ≥ 35 or HAM-A-14 score ≥ 29.\n* 2\\) Presence of significant suicidal ideation.\n* 3\\) History or current diagnosis of neuropsychiatric disorders such as schizophrenia or epilepsy.\n* 4\\) History of head trauma (with loss of consciousness for \\>10 minutes), other unstable major somatic diseases, or any somatic condition that could cause psychiatric symptoms.\n* 5\\) Suspected intellectual disability.\n* 6\\) History of alcohol or substance abuse prior to enrollment.\n* 7\\) Cranial magnetic resonance imaging (MRI) reveals organic lesions.\n* 8\\) Participants who are deemed unsuitable for the study by the investigator for any other reason.","ALL","18 Years","60 Years",{"count":73,"type":74},60,"ESTIMATED","INTERVENTIONAL",[77],"NA","This randomized, double-blind, placebo-controlled study will enroll 60 individuals with mild-to-moderate anxiety depression. Following a 3-month intervention and a 1-month follow-up period, the study aims to: 1) evaluate the efficacy of probiotics by comparing anxiety, depression, and sleep scores to baseline; and 2) investigate the safety and underlying mechanisms by analyzing changes in serum biomarkers, gut microbiota, and related metabolites.",[80],"Anxiety Depression",[82,83,84,85],"Depression","Anxiety","Mood","Probiotics","2026-06-25",{"date":88,"type":89},"2026-06-29","ACTUAL",{"date":91,"type":89},"2026-06-15",{"date":93,"type":74},"2027-02-28",{"name":5,"class":6},1]